RecruitingMelanoma Stage IIIBMelanoma Stage IIICMelanoma Stage IIID
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
Eligible age
18+ yrs
Accepts
All genders
Locations
15 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C/D melanoma patients with respect to the standard of care (surgery and adjuvant therapy).
Sponsor: Philogen S.p.A.
You may qualify if…
- ✓ 1. Histologically or cytologically confirmed diagnosis of clinical stage IIIB, IIIC, and IIID (AJCC 8th edition) locoregional melanoma that is eligible for complete surgical resection of all metastases (surgically resectable).
- ✓ 2. Eligible subjects must have measurable disease and must be candidate for intralesional therapy with at least one injectable cutaneous, subcutaneous, or nodal melanoma lesion (≥ 10 mm in longest diameter) or with multiple injectable lesions that in aggregate have a longest diameter of ≥ 10 mm.
- ✓ 3. Prior anti-tumor treatment for the primary melanoma lesion, including surgery and approved adjuvant treatments (e.g., radiotherapy, immune checkpoint inhibitors, BRAF/MEK inhibitors, etc.) is allowed. Before enrollment in the study, a wash-out period of 6 weeks is required and toxicities from prior treatments should be resumed to Grade ≤1.
- ✓ 4. Males or females, age ≥ 18 years.
- ✓ 5. ECOG Performance Status/WHO Performance Status ≤ 1.
- ✓ 6. Life expectancy of \> 24 months.
- ✓ 7. Absolute neutrophil count \> 1.5 x 109/L.
- ✓ 8. Hemoglobin \> 9.0 g/dL.
You may not qualify if…
- ✕ 1. Uveal melanoma or mucosal melanoma
- ✕ 2. Evidence of distant metastases at screening.
- ✕ 3. Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study except: cervical carcinoma in situ, curatively treated basal cell carcinoma, superficial bladder tumors (Ta, Tis \& T1), second primary melanoma in situ or any cancer curatively treated ≥ 5 years prior to study entry.
- ✕ 4. Presence of active infections (e.g. requiring antimicrobial therapy) or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study.
- ✕ 5. History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris.
- ✕ 6. Inadequately controlled cardiac arrhythmias including atrial fibrillation.
- ✕ 7. Heart insufficiency (\> Grade II, New York Heart Association (NYHA) criteria).
- ✕ 8. LVEF ≤ 50% and/or abnormalities observed during baseline ECG and Echocardiogram investigations that are considered as clinically significant by the investigator.
Where it's recruiting
Arizona
Phoenix
California
La Jolla · Orange
Florida
Tampa
Georgia
Atlanta
Illinois
Chicago
Iowa
Iowa City
Minnesota
Rochester
New Jersey
New Brunswick
New York
New York · Ney York
North Carolina
Durham
Ohio
Columbus
Pennsylvania
Easton · Hershey · Philadelphia
Source: ClinicalTrials.gov · NCT03567889 · last updated 2025-12-17